300086 Honz Pharmaceutical
- 4.14
- +0.04+0.98%
Honz Pharmaceutical News
Kangzhi Pharmaceutical (300086.SZ) announced first-quarter results, with a net loss of 46.5 million yuan, which changed from profit to loss over the previous year
Kangzhi Pharmaceutical (300086.SZ) disclosed its report for the first quarter of 2024. The company achieved revenue of 1.0 during the reporting period...
Kangzhi Pharmaceutical (300086.SZ): Currently mainly selling children's medicines include pediatric antipyretic patches, pediatric detoxifying granules, etc.
Gelonghui, March 8 | Kangzhi Pharmaceutical (300086.SZ) recently said during a survey of institutional investors that the company currently mainly sells levocetirizine hydrochloride granules (exclusive dosage form), ibuprofen granules, pediatric antipyretic patches, pediatric antipyretic granules, ammoniacin granules, aminophen yellow nanamine granules, yinhu cold powder, montmorillonite powder, tannic acid protein yeast powder, lactic acid bacterin granules, gastrointestinal dispersion, Zierling granules, Jianlemeng granules Decalcification powder, cough relief orange red granules, carboxymethane granules, pediatric phlegm granules, pediatric phlegm relief granules, head faclor granules, ribavirin
Kangzhi Pharmaceutical (300086.SZ): Injectable sulamine sodium is a product the company is developing and has not yet been marketed for sale
Gelonghui, January 12 | Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform that injectable sulamine sodium is a product the company is developing and has not yet been marketed for sale. At that time, the research report on the “Horizontal Research Project Research Cooperation Agreement” between the company and the Guangdong Provincial Institute of Public Health had already been released.
Kangzhi Pharmaceutical (300086.SZ): Up to now, no PEEK-related material products have been produced
Gelonghui, January 12 | Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform that currently, the company is a leading domestic children's health enterprise whose main business is the R&D, production and sales of children's medicines, maternal and child health products, and medical devices such as medical protective equipment. The company is closely following the development direction of cutting-edge technology. Up to now, it has not produced PEEK-related material products. Thank you!
Kangzhi Pharmaceutical (300086.SZ): Currently, the company's pharmaceuticals and medical protective equipment are mainly sold domestically
Gelonghui December 20丨Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform that currently the company's pharmaceuticals and medical protective equipment are mainly sold domestically. In the future, the company will continue to explore overseas channels, improve overseas layout, and better meet customer needs for pharmaceuticals and medical device products.
Kangzhi Pharmaceutical (300086.SZ): Currently, the company's montmorillonite is scattered about sales and production, and production capacity is sufficient
On December 20, Gelonghui Pharmaceutical (300086.SZ) stated on the investor interactive platform on December 20 that the company will continue to pay attention to market demand for related drugs and arrange product production plans reasonably. Currently, the company's montmorillonite is scattered about sales and production, and production capacity is sufficient.
Kangzhi Pharmaceutical (300086.SZ): The company is actively and seriously promoting the preparation of annual reports
On December 20, Gelonghui, Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform on December 20 that the company is actively and earnestly promoting the preparation of the annual report. The company will promptly fulfill its obligation to disclose information in the 2023 annual report in accordance with the requirements of relevant laws and regulations.
Kangzhi Pharmaceutical (300086.SZ): The company does not produce or sell mabaloxavir drugs
Glonghui, December 18|Some investors asked Kangzhi Pharmaceutical (300086.SZ) on the investor interactive platform, “Does your company produce mabaloxavir drugs? How are sales volumes?” The company said that the company does not produce or sell mabaloxavir drugs yet.
Kangzhi Pharmaceutical (300086.SZ): Cheng Pengfei resigns as financial director
Gelonghui, December 11, Kangzhi Pharmaceutical (300086.SZ) announced that on December 11, 2023, the board of directors of the company received a written resignation report submitted by Mr. Cheng Pengfei, the financial director. Mr. Cheng Pengfei applied to resign as the company's financial director for personal reasons (the original term was until December 14, 2025), and he did not hold any other position in the company after his resignation. During the period when the company's board of directors did not officially appoint a new financial director, the company's chairman, Mr. Hong Jiangyou, acted as the company's financial director. The company will appoint a new financial director as soon as possible in accordance with the law and regulations.
Kangzhi Pharmaceutical (300086.SZ): 6 pharmaceutical R&D projects that have now entered the registration process
Gelonghui November 30 | Kangzhi Pharmaceutical (300086.SZ) was surveyed by specific targets on November 29, 2023, on “The future direction of the company's self-operated drug development? Does pediatric medicine collect immunity?” The company replied that at present, the company has entered the registration process on 6 pharmaceutical R&D projects. Among them, 3 product development projects, including children's dextromethorphan hydrobromide film and ibuprofen phenylephrine tablets, are currently undergoing clinical research. The company has already participated in the collection of products.
Kangzhi Pharmaceutical (300086.SZ): Products cover the field of adult medicine, and will continue to focus on children's drug research and development innovation in the future
Gelonghui November 30丨Kangzhi Pharmaceutical (300086.SZ) was surveyed by specific targets on November 29, 2023, on “The company's future plans for adult medicine?” The company replied that its products cover the field of adult medicine and will continue to focus on children's drug research and development innovation in the future.
Kangzhi Pharmaceutical (300086.SZ): Sales are mainly agents, and the share of self-employment is relatively low
Gelonghui November 30 | Kangzhi Pharmaceutical (300086.SZ) was surveyed by specific targets on November 29, 2023. Regarding “Please split the current revenue ratio, growth rate, and gross profit margin of self-employment and agents in children's medicine and adult medicine,” the company replied that the company's sales are mainly agents, and the share of self-employment is relatively low. In the first half of 2023, the company's children's drug revenue was 228 million yuan, gross profit margin was 59.13%, operating income increased 75.30% over the same period last year, gross margin increased 14.66% over the same period last year; adult medicine revenue was 556.864 million yuan, gross margin was 49 million yuan.
Kangzhi Pharmaceutical (300086.SZ): Overseas revenue comes from the maternal and child health sector
Gelonghui, November 30丨Kangzhi Pharmaceutical (300086.SZ) was surveyed by specific targets on November 29, 2023. “There has been overseas revenue since 2018. Can you introduce the sources of revenue? Plans for the company to expand overseas in the future?” The company replied that the company's overseas revenue comes from the maternal and child health sector. Relying on the advantages of the Hainan Free Trade Port policy, the sales business team continues to pay attention to overseas expansion market opportunities.
Kangzhi Pharmaceutical (300086.SZ): No products or sales related to diet drugs or weight loss functional compositions
Gelonghui November 8 | Kangzhi Pharmaceutical (300086.SZ) stated on the investor interactive platform that the company has no products or sales related to diet pills or weight loss functional components, yet the company has been closely monitoring the weight loss drug circuit to find suitable related cooperation opportunities. In recent years, under the premise of managing existing pharmaceutical categories well, the company has been actively exploring businesses that are in line with enterprise development strategies, and has continuously improved the exploration, testing, and judgment of drug categories to further focus on management, enhance core competitiveness, expand the company's business scale, and expand new profit growth points.
Kangzhi Pharmaceutical (300086.SZ) sold 100% of Yuanning Pharmaceutical's shares for 12 million yuan
Gelonghui (300086.SZ) announced on October 27, Kangzhi Pharmaceutical (300086.SZ) announced that the company held the 9th meeting of the 6th board of directors on October 25, 2023 to deliberate and pass the “Proposal on the Company's Sale of 100% Shares of Guangdong Yuanning Pharmaceutical Co., Ltd.”. The company will sell 100% of the shares of Guangdong Yuanning Pharmaceutical Co., Ltd. (hereinafter referred to as “Yuanning Pharmaceutical”, “Target Company” or “Target Company”) for RMB 12 million. After the transaction is completed, the company will no longer hold shares in Yuanning Pharmaceutical, and Yuanning Pharmaceutical will no longer be included in the scope of the company's consolidated statements.
Kangzhi Pharmaceutical (300086.SZ) released the first three quarter results, with a net loss of 20,452,500 yuan
Kangzhi Pharmaceutical (300086.SZ) released its report for the third quarter of 2023. The company achieved operating income of 4 in the first three quarters...
Kangzhi Pharmaceutical (300086.SZ): Currently, the company has no plans to repurchase shares
Glonghui, Oct. 25 丨 Some investors asked Kangzhi Pharmaceutical (300086.SZ) on the investor interactive platform, “All listed companies have already announced the launch of repurchases. Will Kangzhi Pharmaceutical also respond to the country's call to firmly believe that China's economy is stable and that China's financial securities market will carry out large-scale repurchases?” The company said that currently the company has no plans to repurchase shares. If the company has a stock repurchase plan in the future, it will promptly fulfill its obligation to disclose information in accordance with the requirements of relevant regulations.
Kangzhi Pharmaceutical (300086.SZ): its wholly-owned subsidiary, Zhongshan Aiyu, has export commodity business
Glonghui, Oct. 11 | Kangzhi Pharmaceutical (300086.SZ) said on the investor interactive platform that at present, the company's products are mainly sold domestically. One of the company's main tasks in recent years is to strengthen the company's marketing team building, strengthen and improve marketing management, increase the depth and breadth of domestic market coverage, and enhance brand reputation and popularity to enhance the company's core competitiveness. Zhongshan Aiyu, a wholly-owned subsidiary of the company, has an export commodity business. If there is a favorable export policy or better market prospects in the later stages, the company will not rule out the possibility of increasing foreign export business, and will continue to pay attention to the development of cross-border e-commerce
Kangzhi Pharmaceutical (300086.SZ) released results for the first half of the year, turning a loss into a profit of 16.311,400 yuan
Kangzhi Pharmaceutical (300086.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Honz Pharmaceutical Co., Ltd.'s (SZSE:300086) Business Is Yet to Catch Up With Its Share Price
When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.5x, Honz Pharmaceutical Co., Ltd. (SZSE:300086) looks to be giving
Analysis
Price Target
No Data
